Our work is aimed at unraveling the role of the first-phase insulin secretion in the natural
history of type 2 diabetes mellitus (T2DM) and its interrelationship with insulin resistance …

Type 2 diabetes mellitus (T2DM) is a worldwide public health challenge. Despite the
availability of many antidiabetes agents and pharmacotherapies targeting cardiovascular …

A worldwide pandemic of obesity and diabetes is well advanced. In the United States alone,
diabetes now affects an estimated 24.1 million people, an increase of more than 3 million in …

OBJECTIVE This study tests the effectiveness of expert guidelines for diabetes prevention:
lifestyle intervention with addition of metformin, when required, among people with …

Aim: To show that vildagliptin added to metformin is non‐inferior to glimepiride in reducing
HbA1c levels from baseline over 2 years. Methods: A randomized, double‐blind, active …

Background Berberine is a plant alkaloid that has multiple beneficial effects against intestine
inflammation. In our previous study, we have found that berberine also possesses an …

Inhibition of dipeptidyl peptidase‐4 (DPP‐4) by vildagliptin prevents degradation of
glucagon‐like peptide‐1 (GLP‐1) and reduces glycaemia in patients with type 2 diabetes …

Context: Dipeptidyl peptidase 4 (DPP-4) inhibitors have been widely used in type 2
diabetes. An important unanswered question concerns the effect of DPP-4 inhibition on β …

Context: Dipeptidyl peptidase-4 inhibitors act by increasing plasma levels of glucagon-like
peptide-1 and suppressing excessive glucagon secretion in patients with type 2 diabetes …

Achieving and maintaining recommended glycemic targets without causing adverse e ffects,
including hypoglycemia, is challenging, especially in older patients with type 2 diabetes …